Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the medical research company’s stock.

Several other equities research analysts also recently commented on AXDX. William Blair restated an “outperform” rating on shares of Accelerate Diagnostics in a research note on Tuesday, April 2nd. Craig Hallum cut their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a report on Monday, April 1st.

Accelerate Diagnostics Price Performance

Shares of AXDX stock opened at $0.86 on Friday. The stock’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $3.16. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $11.90. The firm has a market cap of $18.61 million, a price-to-earnings ratio of -0.18 and a beta of 0.52.

Hedge Funds Weigh In On Accelerate Diagnostics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Sonora Investment Management Group LLC bought a new position in shares of Accelerate Diagnostics in the third quarter valued at about $63,000. Swiss National Bank raised its stake in shares of Accelerate Diagnostics by 19.0% in the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock worth $123,000 after acquiring an additional 13,600 shares during the last quarter. Tejara Capital Ltd acquired a new position in shares of Accelerate Diagnostics during the third quarter worth approximately $78,000. Virtu Financial LLC lifted its position in shares of Accelerate Diagnostics by 95.4% during the fourth quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock worth $25,000 after purchasing an additional 17,461 shares in the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of Accelerate Diagnostics during the first quarter valued at approximately $27,000. Institutional investors and hedge funds own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.